Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,670Revenue $M619Net Margin (%)-4.9Z-Score10.3
Enterprise Value $M8,396EPS $-0.2Operating Margin %-14.1F-Score4
P/E(ttm))0Cash Flow Per Share $0.0Pre-tax Margin (%)-2.3Higher ROA y-yN
Price/Book6.110-y EBITDA Growth Rate %0Quick Ratio6.3Cash flow > EarningsY
Price/Sales14.05-y EBITDA Growth Rate %0Current Ratio6.7Lower Leverage y-yY
Price/Cash Flow725y-y EBITDA Growth Rate %-33.3ROA % (ttm)-1.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-2.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M148ROI % (ttm)-2.4Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSKen Fisher 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 58.5513%Add 10.18%107,164
ALKSVanguard Health Care Fund 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 58.5513%Add 0.05%6,226,383
ALKSVanguard Health Care Fund 2014-09-30 Add0.01%$41.54 - $51.75
($44.82)
$ 58.5523%Add 1.42%6,223,083
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 58.5524%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 58.5521%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 58.5521%New holding55,309
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 58.5519%Add 41.07%5,180,238
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 58.5537%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 58.5544%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 58.5544%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 58.5550%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 58.5550%New holding26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 58.5563%Add 47.24%1,233,024
ALKSVanguard Health Care Fund 2012-06-30 Add$15.12 - $18.64
($16.96)
$ 58.5571%Add 6.28%837,400
ALKSVanguard Health Care Fund 2012-03-31 Buy 0.07%$16.14 - $19.5
($16.48)
$ 58.5572%New holding787,900
ALKSJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.41 - $14.01
($11.62)
$ 58.5580%Sold Out0
ALKSGeorge Soros 2010-03-31 Sold Out $9.41 - $14.01
($11.62)
$ 58.5580%Sold Out0
ALKSGeorge Soros 2009-12-31 Buy $7.58 - $9.88
($8.72)
$ 58.5585%New holding22,800
ALKSJean-Marie Eveillard 2009-09-30 Buy 0.01%$8.75 - $11.65
($10.13)
$ 58.5583%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cooke ShanePresident, Alkermes plc 2015-04-23Sell18,000$62.55-0.46view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2015-04-21Sell25,000$62.39-0.21view
MITCHELL PAUL JDirector 2015-04-15Sell1,500$62.71-0.72view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2015-04-15Sell13,750$63.21-1.5view
FRATES JAMES MSVP & CFO, Alkermes plc 2015-04-15Sell10,000$62.42-0.26view
BREYER ROBERT ADirector 2015-04-01Sell5,000$61.221.7view
Cooke ShanePresident, Alkermes plc 2015-03-23Sell18,000$65.33-4.7view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2015-03-16Sell18,000$66.81-6.81view
FRATES JAMES MSVP & CFO, Alkermes plc 2015-03-10Sell10,000$66.25-6.02view
Peterson RebeccaSVP, Corporate Communications 2015-03-05Sell17,737$71.37-12.76view

Press Releases about ALKS :

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
wait for positive ea Apr 06 2013 
comment on ALKS Mar 09 2013 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 


More From Other Websites
Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 23 2015
Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 23 2015
Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Apr 23 2015
ALKERMES PLC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements... Apr 16 2015
ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Apr 13 2015
Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™)... Apr 13 2015
Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™)... Apr 13 2015
Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™)... Apr 13 2015
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead -... Apr 09 2015
Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog Apr 07 2015
Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS... Apr 06 2015
Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS... Apr 06 2015
Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS... Apr 06 2015
Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog Mar 30 2015
Alkermes 'Taking A Pause,' Citi Says Mar 27 2015
Alkermes plc -- Moody's affirms Alkermes' Ba3 ratings; changes outlook to stable Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog Mar 10 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK